ArticleEClinicalMedicine2025

Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study).

Wei Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.